Final answer:
The ideal candidate for Reslizumab, an IL-5 inhibitor, is a patient with severe eosinophilic asthma.
Step-by-step explanation:
The ideal candidate for Reslizumab, an IL-5 inhibitor, would be a patient with severe eosinophilic asthma. Eosinophils are a type of white blood cell that play a role in asthma inflammation. Reslizumab works by blocking the IL-5 pathway, reducing the number of eosinophils and decreasing airway inflammation.
In a study published in the Journal of Allergy and Clinical Immunology, Reslizumab was shown to be effective in reducing asthma exacerbations and improving lung function in patients with severe eosinophilic asthma. It is specifically indicated for patients aged 18 years and older who have a history of asthma exacerbations despite being on high-dose inhaled corticosteroids.